ClinicalTrials.gg
CompletedNCT02984982ODYSSEY J-IVUSUpdated Sep 9, 2019Results posted

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

A Phase 4 interventional study of Alirocumab SAR236553 and Atorvastatin in Hypercholesterolemia and Acute Coronary Syndrome, sponsored by Sanofi. Completed at 39 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
18th of 43
206 · median 107
Started
2016
with 4 others
Phase 4
5 of 43
1 open now
Registered
36th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 18th largest by enrollment, is one of 5 that started in 2016, is one of 5 in phase 4, and was the 36th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To compare the efficacy of alirocumab (Praluent®) with standard of care (SoC) on coronary atheroma progression (percent change in normalized total atheroma volume [TAV]) after 9 months of treatment in participants who had acute coronary syndrome (ACS) within 4 weeks prior to randomization, with hypercholesterolemia treated with statin.

Secondary Objectives:

  • To compare the efficacy of alirocumab (Praluent®) with SoC on secondary endpoints including absolute change in percent atheroma volume and normalized TAV after 9 months of treatment.
  • To evaluate the efficacy of alirocumab (Praluent®) on low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, triglycerides, non-high-density lipoprotein cholesterol and lipoprotein (a) after 9 months treatment.
  • To evaluate the safety of alirocumab (Praluent®) including the occurrence of cardiovascular events (coronary heart disease death, non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) throughout the study.
Read the detailed description

The duration of study per participant was 9 months.

03

Conditions studied

  • Hypercholesterolemia
  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants hospitalized for ACS (Acute ST-segment elevation myocardial infarction [STEMI], Acute non-ST-segment elevation myocardial infarction [NSTEMI], and unstable angina.
  • LDL-C >=100 mg/dL at ACS diagnosis.
  • Participants who has stenosis with at least >50% stenosis angiographically within 1 week after the ACS onset, and has analyzable coronary intravascular Ultrasound image.
  • Participants aged >=20 years old at ACS diagnosis.
  • Negative surface antigen, negative Hepatitis B core antibody, and negative antibody. Or, negative Hepatitis B surface antigen, positive Hepatitis B core antibody, negative Hepatitis B deoxyribonucleic acid, and negative Hepatitis C antibody.
  • Written .

Exclusion criteria

Exclusion criteria:

  • Participants who had previously treated with at least one dose of any anti-proprotein convertase subtilisin/kexin type 9 monoclonal antibody.
  • Uncontrolled hypertension (multiple reading with systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) between ACS diagnosis and randomization visit.
  • Known history of hemorrhagic stroke.
  • Currently under treatment for cancer.
  • Participants on LDL apheresis.
  • Any abnormality identified that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases, participants with short .
  • Considered by the Investigator or any sub-Investigator as inappropriate for this study for any reason, including:

    • Unable to meet specific protocol requirements, such as scheduled visits;
    • Investigator or any sub-Investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol, etc;
    • Presence of any other conditions (eg, geographic, social, etc.) actual or anticipated, that the Investigator feels would restrict or limit the participant's participation for the duration of the study.
  • Laboratory findings measured within 4 weeks after the ACS diagnosis (positive serum or urine pregnancy test in females of ).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Active comparator
    Standard of Care

    Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level \<100 milligrams per deciliter (mg/dL).

    Drug: Atorvastatin · Drug: Rosuvastatin · Drug: Fenofibrate · Drug: Bezafibrate · Drug: Ezetimibe · Drug: Antiplatelets · Drug: Anticoagulants

  • Experimental
    Alirocumab

    Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.

    Drug: Alirocumab SAR236553 · Drug: Atorvastatin · Drug: Rosuvastatin · Drug: Fenofibrate · Drug: Bezafibrate · Drug: Ezetimibe · Drug: Antiplatelets · Drug: Anticoagulants

Interventions

  • Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

    Also known as: Praluent

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • DrugAntiplatelets

    Pharmaceutical form: tablet or capsule Route of administration: oral

  • DrugAnticoagulants

    Pharmaceutical form: tablet or capsule Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36

    Least-squares (LS) means and standard errors (SE) at Week 36 were obtained from analysis of covariance (ANCOVA) model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36

    LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline PAV as continuous fixed covariate.

    Time frame: Baseline, Week 36

  2. Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36

    LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.

    Time frame: Baseline, Week 36

  3. Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36

    Adjusted mean and SE at Week 36 were obtained from robust regression model with treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]), as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  4. Percent Change From Baseline in External Elastic Membrane Volume at Week 36

    Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  5. Absolute Change From Baseline in Lumen Volume at Week 36

    Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline lumen volume value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  6. Percent Change From Baseline in Lumen Volume at Week 36

    Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and the baseline lumen volume value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  7. Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

    Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 12, Week 36

  8. Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

    Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 12, Week 36

  9. Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  10. Percent Change From Baseline in Apolipoprotein B at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  11. Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 36

  12. Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 36

  13. Absolute Change From Baseline in Total Cholesterol (TC) at Week 36

    LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated TC value and baseline calculated TC value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 36

  14. Percent Change From Baseline in Total Cholesterol at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline TC value and baseline TC value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 36

  15. Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36

    Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  16. Percent Change From Baseline in Lipoprotein (a) at Week 36

    Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  17. Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 36

  18. Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.

    Time frame: Baseline, Week 36

  19. Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36

    Adjusted mean and SE were obtained from multiple imputation approach followed by robust regression model including fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.

    Time frame: Baseline, Week 36

  20. Percent Change From Baseline in Fasting Triglycerides at Week 36

    Adjusted mean and SE were obtained by multiple imputation approach followed by robust regression model included fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.

    Time frame: Baseline, Week 36

  21. Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  22. Percent Change From Baseline in Apolipoprotein A-1 at Week 36

    Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.

    Time frame: Baseline, Week 36

  23. Number of Participants With Cardiovascular (CV) Adverse Events

    The suspected or confirmed CV events that occurred from randomization until end of the study visit were collected and reported. The various CV events included CV death, myocardial infarction, ischemic stroke, unstable angina requiring hospitalization , congestive heart failure requiring hospitalization, congestive heart failure requiring hospitalization, ischemia-driven coronary revascularization procedure.

    Time frame: Up to 36 weeks

07

Results

Posted Sep 9, 2019

Participant flow

The study was conducted at 39 active centers in Japan. Overall 214 participants were screened between 15 November 2016 and 02 November 2017, of whom 8 were screen failure and 206 were randomized to either alirocumab arm or standard of care (SoC) arm.

Participant flow — Overall Study
MilestoneStandard of CareAlirocumab
Started102104
Treated102103
Completed9494
Not completed810
Withdrew: Adverse event25
Withdrew: Poor compliance to protocol44
Withdrew: Withdrawal by subject20
Withdrew: Randomized but not treated01

Outcome measures

PrimaryPercent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36

Least-squares (LS) means and standard errors (SE) at Week 36 were obtained from analysis of covariance (ANCOVA) model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36-3.14 ± 0.97-4.79 ± 0.95
Statistical analysis
  • Standard of Care vs Alirocumab · ANCOVA · p = 0.2279 (Threshold for significance at 0.05 level.) · Ls mean difference: -1.64 · 95% CI -4.32 to 1.04Standard of Care vs Alirocumab
SecondaryAbsolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36

LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline PAV as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent atheroma volume
Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36
percent atheroma volumeStandard of CareAlirocumab
Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36-1.28 ± 0.39-1.42 ± 0.38
SecondaryAbsolute Change From Baseline in Normalized Total Atheroma Volume at Week 36

LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · cubic millimeter (mm^3)
Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36
cubic millimeter (mm^3)Standard of CareAlirocumab
Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36-4.73 ± 1.02-5.77 ± 1.00
SecondaryAbsolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model with treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]), as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Mean · mm^3
Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36
mm^3Standard of CareAlirocumab
Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36-8.23 ± 1.85-10.01 ± 1.81
SecondaryPercent Change From Baseline in External Elastic Membrane Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Mean · percent change
Percent Change From Baseline in External Elastic Membrane Volume at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in External Elastic Membrane Volume at Week 36-0.86 ± 0.93-3.18 ± 0.91
SecondaryAbsolute Change From Baseline in Lumen Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and the baseline lumen volume value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Mean · mm^3
Absolute Change From Baseline in Lumen Volume at Week 36
mm^3Standard of CareAlirocumab
Absolute Change From Baseline in Lumen Volume at Week 36-1.25 ± 1.38-0.93 ± 1.35
SecondaryPercent Change From Baseline in Lumen Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and the baseline lumen volume value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Mean · percent change
Percent Change From Baseline in Lumen Volume at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Lumen Volume at Week 361.20 ± 1.26-0.86 ± 1.23
SecondaryAbsolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 12, Week 36
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
mg/dLStandard of CareAlirocumab
Week 12-9.6 ± 1.7-62.4 ± 1.6
Week 36-15.5 ± 1.8-63.2 ± 1.8
SecondaryPercent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 12, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
percent changeStandard of CareAlirocumab
Week 12-7.57 ± 1.91-64.53 ± 1.83
Week 36-13.40 ± 1.99-63.94 ± 1.91
SecondaryAbsolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36
mg/dLStandard of CareAlirocumab
Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36-16.8 ± 1.4-51.0 ± 1.3
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Apolipoprotein B at Week 36-16.61 ± 1.56-55.13 ± 1.53
SecondaryAbsolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36
mg/dLStandard of CareAlirocumab
Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36-20.3 ± 2.0-69.2 ± 2.0
SecondaryPercent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36-14.06 ± 1.71-54.50 ± 1.67
SecondaryAbsolute Change From Baseline in Total Cholesterol (TC) at Week 36

LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated TC value and baseline calculated TC value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Total Cholesterol (TC) at Week 36
mg/dLStandard of CareAlirocumab
Absolute Change From Baseline in Total Cholesterol (TC) at Week 36-15.2 ± 2.3-61.7 ± 2.2
SecondaryPercent Change From Baseline in Total Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline TC value and baseline TC value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Total Cholesterol at Week 36-7.59 ± 1.35-35.43 ± 1.32
SecondaryAbsolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36
mg/dLStandard of CareAlirocumab
Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36-10.3 ± 0.5-15.5 ± 0.5
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Lipoprotein (a) at Week 36-17.23 ± 2.60-55.76 ± 2.54
SecondaryAbsolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
mg/dLStandard of CareAlirocumab
Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 364.7 ± 0.98.1 ± 0.9
SecondaryPercent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset \[Yes / No\]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 3612.19 ± 2.3021.04 ± 2.25
SecondaryAbsolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36

Adjusted mean and SE were obtained from multiple imputation approach followed by robust regression model including fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.

Time frame:
Baseline, Week 36
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36
mg/dLStandard of CareAlirocumab
Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36-26.2 ± 4.7-35.3 ± 4.5
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 36

Adjusted mean and SE were obtained by multiple imputation approach followed by robust regression model included fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) and the continuous fixed covariate of baseline fasting TGs value.

Time frame:
Baseline, Week 36
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Fasting Triglycerides at Week 36-8.85 ± 3.62-18.37 ± 3.51
SecondaryAbsolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36
mg/dLStandard of CareAlirocumab
Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 363.8 ± 1.912.0 ± 1.9
SecondaryPercent Change From Baseline in Apolipoprotein A-1 at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset \[Yes / No\]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 at Week 36
percent changeStandard of CareAlirocumab
Percent Change From Baseline in Apolipoprotein A-1 at Week 364.61 ± 1.6211.75 ± 1.58
SecondaryNumber of Participants With Cardiovascular (CV) Adverse Events

The suspected or confirmed CV events that occurred from randomization until end of the study visit were collected and reported. The various CV events included CV death, myocardial infarction, ischemic stroke, unstable angina requiring hospitalization , congestive heart failure requiring hospitalization, congestive heart failure requiring hospitalization, ischemia-driven coronary revascularization procedure.

Time frame:
Up to 36 weeks
Reported as:
Count of participants · Participants
Number of Participants With Cardiovascular (CV) Adverse Events
ParticipantsStandard of CareAlirocumab
Cardiovascular death00
Myocardial infarction32
Ischemic stroke02
Unstable angina requiring hospitalization00
Congestive heart failure requiring hospitalization00
Ischemia led coronary revascularization procedure24

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 21 days after last dose of study drug, or end of study, whichever comes first (up to 39 weeks) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care1/102 (1%)17/102 (16.7%)15/102 (14.7%)
Alirocumab0/103 (0%)19/103 (18.4%)33/103 (32%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventStandard of CareAlirocumab
Myocardial ischaemiaCardiac disorders3/1021/103
Coronary artery stenosisCardiac disorders0/1023/103
PneumoniaInfections and infestations2/1021/103
Acute myocardial infarctionCardiac disorders2/1022/103
Myocardial infarctionCardiac disorders2/1021/103
Cerebral infarctionNervous system disorders0/1022/103
SepsisInfections and infestations1/1020/103
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1020/103
Transient ischaemic attackNervous system disorders1/1021/103
Acute coronary syndromeCardiac disorders1/1020/103
Most frequent other events
Most frequent other events
EventStandard of CareAlirocumab
NasopharyngitisInfections and infestations15/10227/103
Injection site reactionGeneral disorders0/1027/103
Back painMusculoskeletal and connective tissue disorders0/1026/103

Baseline characteristics

Randomized population included all participants who were allocated to a randomized treatment and recorded in the registration center database, regardless of whether a study drug was used or not.

Age, Continuous
Age, Continuous(years)Standard of CareAlirocumabTotal
Mean60.0 ± 11.961.7 ± 10.960.9 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Standard of CareAlirocumabTotal
Female192140
Male8383166
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Standard of CareAlirocumabTotal
American Indian or Alaska Native000
Asian102104206
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Standard of CareAlirocumabTotal
Mean95.2 ± 22.698.5 ± 22.996.9 ± 22.8
08

Study locations

39 sites
  • Investigational Site Number 392026
    Bunkyō-Ku, Japan
  • Investigational Site Number 392022
    Chiyoda-ku, Japan
  • Investigational Site Number 392032
    Fujisawa-shi, Japan
  • Investigational Site Number 392004
    Fukui-shi, Japan
  • Investigational Site Number 392007
    Fukuoka-shi, Japan
  • Investigational Site Number 392048
    Fukuoka-shi, Japan
  • Investigational Site Number 392008
    Gifu-shi, Japan
  • Investigational Site Number 392039
    Hiroshima-shi, Japan
  • Investigational Site Number 392028
    Isehara-shi, Japan
  • Investigational Site Number 392036
    Itabashi-ku, Japan
  • Investigational Site Number 392037
    Itabashi-ku, Japan
  • Investigational Site Number 392024
    Izumisano-shi, Japan
  • Investigational Site Number 392013
    Izunokuni-shi, Japan
  • Investigational Site Number 392020
    Kawaguchi-shi, Japan
  • Investigational Site Number 392009
    Kitakyushu-shi, Japan
  • Investigational Site Number 392034
    Kitakyushu-shi, Japan
  • Investigational Site Number 392044
    Kochi-shi, Japan
  • Investigational Site Number 392002
    Kumamoto-shi, Japan
  • Investigational Site Number 392011
    Kumamoto-shi, Japan
  • Investigational Site Number 392003
    Kurashiki-shi, Japan
  • Investigational Site Number 392018
    Matsuyama-shi, Japan
  • Investigational Site Number 392021
    Morioka-shi, Japan
  • Investigational Site Number 392017
    Nagakute-shi, Japan
  • Investigational Site Number 392047
    Nagaoka-shi, Japan
  • Investigational Site Number 392033
    Okayama-shi, Japan
  • Investigational Site Number 392006
    Osaka-shi, Japan
  • Investigational Site Number 392010
    Osaka-shi, Japan
  • Investigational Site Number 392045
    Osaka-shi, Japan
  • Investigational Site Number 392046
    Osaka-shi, Japan
  • Investigational Site Number 392015
    Sagamihara-shi, Japan
  • Investigational Site Number 392019
    Sakai-shi, Japan
  • Investigational Site Number 392035
    Sapporo-shi, Japan
  • Investigational Site Number 392001
    Tenri-shi, Japan
  • Investigational Site Number 392016
    Toyoake-shi, Japan
  • Investigational Site Number 392025
    Tsukuba-shi, Japan
  • Investigational Site Number 392040
    Tsukuba-shi, Japan
  • Investigational Site Number 392005
    Wakayama-shi, Japan
  • Investigational Site Number 392027
    Yokohama-shi, Japan
  • Investigational Site Number 392043
    Yokohama-shi, Japan
09

References and documents

Publications

  • Ako J, Hibi K, Tsujita K, Hiro T, Morino Y, Kozuma K, Shinke T, Otake H, Uno K, Louie MJ, Takagi Y, Miyauchi K. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial. Circ J. 2019 Sep 25;83(10):2025-2033. doi: 10.1253/circj.CJ-19-0412. Epub 2019 Aug 20. PubMed 31434809 ↗
  • Ako J, Hibi K, Kozuma K, Miyauchi K, Morino Y, Shinke T, Tsujita K, Uno K, Kawabata Y, Hiro T. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. J Cardiol. 2018 Jun;71(6):583-589. doi: 10.1016/j.jjcc.2017.11.013. Epub 2018 Mar 30. PubMed 29606415 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Not available for request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2018, 20 months.

Results were first posted in Sep 2019, 1 year 1 month after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2016
First posted
Dec 7, 2016
StartActual
Nov 15, 2016
Primary completionActual
Jul 27, 2018
CompletionActual
Jul 27, 2018
Results first posted
Sep 9, 2019
Last update
Sep 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02984982
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 7, 2016
Start date
Nov 15, 2016
Primary completion
Jul 27, 2018
Completion
Jul 27, 2018
Results posted
Sep 9, 2019
Last update
Sep 9, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion